Archives: News

Filter products:

BIOHIT Appoints Market Access & Development Manager

BIOHIT HealthCare Ltd are pleased to announce the appointment of Angela Gore as Market Access & Development Manager.

Following a successful few years of growth at BIOHIT, this announcement sees the expansion of the BIOHIT team. This new role will focus on developing networks within the NHS, improving the exposure of BIOHIT’s key products, and broadening the company’s market reach into new areas.

BIOHIT HealthCare to host webinar exploring TDM in gastrointestinal medicine

BIOHIT HealthCare is excited to announce its upcoming webinar entitled Proactive vs reactive therapeutic drug monitoring in inflammatory bowel disease (IBD). The event will take place on the 26th of October at 11 am, and will include a live Q&A with the expert speakers, Professor Jimmy Limdi and Dr Christian Selinger and moderated by The Clinical Services Journal.

BIOHIT is exhibiting at the BSI congress 2022

BIOHIT is excited to be exhibiting at this year’s British Society for Immunology (BSI) Congress in Liverpool. The UK’s premier immunology event, taking place from the 5th to 8th of December, welcomes over 1,500 attendees – including scientists, researchers and clinical specialists – to witness a fascinating fusion of innovative research from around the world.

BIOHIT launches new quick test to help streamline gastroscopy referrals

BIOHIT Ltd will be attending the upcoming BSG Live 2023 conference in Liverpool, where it will unveil a revolutionary new test to support decision making for gastroscopy referrals and improve the early detection of gastric cancer. The GastroPanel® Quick Test diagnoses Helicobacter pylori infection, atrophic gastritis (AG) – a precancerous condition – and high gastric acid output in just 15 minutes, helping to triage patients in primary care and promote early discovery and treatment of gastrointestinal disorders.

BIOHIT to launch the GastroPanel® Quick Test at BSG LIVE’23

BIOHIT is excited to launch its GastroPanel Quick Test at BSG LIVE’23, which will take place from the 19th to the 22nd of June at the Arena and Conference Centre (ACC) Liverpool. This annual meeting provides the ideal opportunity to share this innovation with colleagues in the gastroenterology and hepatology community, as they come together to discuss the latest advances in the field.

BIOHIT to present GastroPanel® Quick Test at IBMS Congress 2023

BIOHIT is pleased to announce its attendance at IBMS Congress 2023, where it will showcase its new GastroPanel® Quick Test for triaging gastroscopy referrals. The prestigious annual event promises to be the UK’s largest biomedical science exhibition, and will feature over 300 lectures covering 13 medical disciplines, exploring the latest technological advances, products, services and equipment in the rapidly evolving field of laboratory medicine.

Joining forces to improve laryngopharyngeal reflux diagnosis

BIOHIT HealthCare is pleased to extend its corporate partnership with the British Laryngological Association (BLA) for a second year running, supporting its pursuit of improved diagnosis for laryngopharyngeal reflux (LPR).

Wraparound IBD care pathway for enhanced patient outcomes

BIOHIT is pleased to announce its partnership with Celltrion Healthcare UK Ltd, providing point-of-care assays for the Celltrion Connect Dedicated Homecare Service, which is designed to seamlessly support patients with inflammatory bowel disease (IBD) and their healthcare providers. BIOHIT will be supplying the Preventis SmarTest® Calprotectin Home test – a digital self-test system that combines a faecal calprotectin test with a smartphone app to help patients to monitor their condition in the comfort of their own homes.

BIOHIT becomes corporate partner of the British Laryngological Association

Today BIOHIT are pleased to announce they have become the corporate partner of the British Laryngological Association (BLA) for 2022-2023. This partnership brings together two organisations that are striving to achieve advancements in laryngology for the benefit of the patient and healthcare providers.

BIOHIT offers home-testing option for IBD patients

BIOHIT is pleased to announce that it is now the exclusive UK and Ireland distributor of Preventis GmbH’s SmarTest® Calprotectin Home, a digital self-test system that combines a faecal calprotectin test with a smartphone app. The innovative product has been designed especially for patients with chronic inflammatory bowel disease (IBD) and allows individuals to routinely self-monitor their disease activity by quantitatively measuring their faecal calprotectin levels at home.

BIOHIT HealthCare is attending BSG LIVE ’22 this June

BIOHIT is excited to be exhibiting at the upcoming BSG LIVE ’22 at the ICC in Birmingham. This event, which takes place from the 20th to 23rd of June, showcases the latest clinical and educational developments within gastroenterology and hepatology.

The new online face of BIOHIT

BIOHIT is pleased to announce the launch of its new website. This new look and feel is designed to reflect the company’s vision, mission and values, while making it easier than ever for customers and partners to find the information they need. Visitors to the site can now quickly navigate to the disease area or products of interest, and there is also a resource section to provide rapid access to brochures, webinars, case studies and blogs.

Study confirms accuracy of new generation GastroPanel® test for non-invasive diagnosis of atrophic gastritis and Helicobacter pylori infection

A clinical validation study conducted at Oulu University Hospital (OUH) has confirmed the high accuracy of BIOHIT Oyj’s new generation GastroPanel® test for the diagnosis of atrophic gastritis (AG) and Helicobacter pylori (Hp) infection in patients referred for gastroscopy.1 This unique blood test is designed for the first-line diagnosis of Hp infection and AG in patients with upper abdominal symptoms, such as dyspepsia and gastro-oesophageal reflux disease (GORD), before endoscopy. GastroPanel is also the only test on the market capable of monitoring the regulatory mechanism of acid output in the stomach.

BIOHIT supplies rapid turbidimetric GI test kits

BIOHIT Ltd is now distributing three new particle enhanced turbidimetric immunoassays (PETIAs) for the rapid and differential diagnosis of gastrointestinal (GI) diseases.

BIOHIT’s test panel for stomach health backed by further evidence

A recent study published by the research group of Professor Francesco Di Mario at Parma University, Italy, found a strong relationship between low levels of plasma Gastrin-17 (G-17) and the manifestation of gastro-oesophageal reflux disease (GORD).